Yelin Lapidot Holdings Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Yelin Lapidot Holdings Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-96,297	Closed	-$2.25M	–	88
2026 Q1	$2.25M	Sell	96,297 -12,080	-11%	-$262K	0.47%	39
2025 Q4	$2.28M	Hold	108,377	–	–	0.46%	42
2025 Q3	$1.67M	Hold	108,377	–	–	0.35%	53
2025 Q2	$1.01M	Hold	108,377	–	–	0.19%	63
2025 Q1	$1.33M	Hold	108,377	–	–	0.26%	58
2024 Q4	$1.43M	Hold	108,377	–	–	0.25%	55
2024 Q3	$2.09M	Sell	108,377 -6,153	-5%	-$127K	0.34%	44
2024 Q2	$2.35M	Hold	114,530	–	–	0.41%	43
2024 Q1	$2.73M	Hold	114,530	–	–	0.56%	42
2023 Q4	$2.47M	Hold	114,530	–	–	0.6%	35
2023 Q3	$1.79M	Buy	+114,530	New	+$2.17M	0.44%	43

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Yelin Lapidot Holdings Management's SNDX Position: Q2 2026 in Review

Yelin Lapidot Holdings Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 96,297 shares — an estimated $2.25M sold.

Yelin Lapidot Holdings Management first reported a position in SNDX in Q3 2023 and held it in 11 quarters. The position peaked at $2.73M in Q1 2024. 71 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Yelin Lapidot Holdings Management reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Yelin Lapidot Holdings Management sold 96,297 Syndax Pharmaceuticals shares in Q2 2026, an estimated $2.25M.
Yelin Lapidot Holdings Management first reported a position in Syndax Pharmaceuticals in Q3 2023 and held it in 11 quarters.
Yelin Lapidot Holdings Management's Syndax Pharmaceuticals position peaked at $2.73M in Q1 2024.
71 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Yelin Lapidot Holdings Management's 13F filing for Q2 2026, filed 3 Aug 2026.